Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
09/2003
09/17/2003EP0996446B1 Novel substituted imidazole compounds
09/17/2003EP0571613B1 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
09/17/2003CN1443241A Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, proteins encoded, and uses thereof
09/17/2003CN1443199A Antibodies to human MCP-1
09/17/2003CN1443187A Fused cyclic compounds as modulators of nuclear hormone receptor function
09/17/2003CN1443186A Thiazolidinedione salt for treatment of diabetes mellitus
09/17/2003CN1443185A 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2, 4-dione hydriodide as pharmaceutical
09/17/2003CN1443184A 嘧啶衍生物 Pyrimidine derivatives
09/17/2003CN1443179A Aniline derivatives
09/17/2003CN1443178A (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphtyl] -4-morpholibenzamide
09/17/2003CN1443177A Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
09/17/2003CN1443176A Valsartan salts
09/17/2003CN1443167A Azacyclic compounds for use in treatment of 5-serotonin related diseases
09/17/2003CN1443164A Pyrrolidine derivatives as metalloprotease inhibitors
09/17/2003CN1443163A Pyrrolidine-2-carboxylic acid hydrozide derivatives for use as metalloprotease inhibitors
09/17/2003CN1443162A New combination of serotonin agonist (5HT2) and antagonist (5HT6) as pharmaceutical formulation
09/17/2003CN1443161A Aryl sulfonamides as serotonin antagonist for treatment of obesity
09/17/2003CN1443085A Method for locating compounds which are suitable for treatment and/or prophylaxis of obesity
09/17/2003CN1443068A Combinations of depepotidyl peptidase IV inhibitors and other antidiabetic agents for treatment of diabete mellitus
09/17/2003CN1443065A Pharmaceutical composition improved in peroral absorbability
09/17/2003CN1442399A Method of converting inositol derivative in bitter buckwheat seed into its monomer and its extraction product
09/17/2003CN1442202A Biological preparation for preventing and treating heart and brain blood vessel disease and its application
09/17/2003CN1442161A Pad for lowering blood viscous and blood fat
09/17/2003CN1442148A Daidzein drip pill and its preparation method
09/17/2003CN1442146A New pharmaceutical of cactus total flavone and its preparation method
09/17/2003CN1442139A Medicinal composition for treating inflammation
09/17/2003CN1121385C Haphthyl compounds, intermediates, compositions and methods of use
09/17/2003CN1121374C Novel trienoic retinoid compounds and method
09/17/2003CN1121221C Medicine preparation containing ferrous saccharin
09/16/2003US6620967 Ketosis-treating agent
09/16/2003US6620941 Process for the preparation of thiazolidinedione derivatives
09/16/2003US6620915 Monoclonal antibodies specific for integrin α-d subunit
09/16/2003US6620910 Of given amino acid sequence; receptor agonists; increased metabolic stability; longer duration of action; use in treatment of non-insulin-dependent type II diabetes, obesity, and type I diabetes
09/16/2003US6620840 Derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them
09/16/2003US6620827 PPARγ modulators
09/16/2003US6620821 HMG-CoA reductase inhibitors and method
09/16/2003US6620820 Inhibitors of bone reabsorption and antagonists of vitronectin receptors
09/16/2003US6620809 Substituted (dihydro)benzoxazine and (dihydro)benzothiazine compounds
09/16/2003US6620806 Estrogen agonist/antagonist to prevente myocardial infarction or stroke, maintaining or improving vascular reactivity, treat renal failure, peripheral arterial occlusive disease, coronary artery disease, or raynaud's phenomenon
09/16/2003US6620789 Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs
09/16/2003US6620782 compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or
09/16/2003US6620594 Uncoupling protein homologue: UCP 3
09/16/2003US6620424 Process for producing glycolytic metabolism regulators
09/16/2003CA2249009C Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
09/16/2003CA2235421C Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
09/16/2003CA2232116C Novel n-aryl piperidine compounds, process for their preparation and pharmaceutical compositions containing them
09/16/2003CA2231025C Novel compounds of 2-aminoindane, process for their preparation and pharmaceutical compositions containing them
09/16/2003CA2025490C Novel substituted alkyl piperidines and their use as inhibitors of cholesterol synthesis
09/16/2003CA2019404C 11 beta-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents
09/12/2003WO2003074711A1 Expression cassette for persistence of expression of a gene of interest in muscle cells
09/12/2003WO2003074694A1 Adipocyte differentiation-associated genes and proteins
09/12/2003WO2003074654A2 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
09/12/2003WO2003074564A1 Novel hemepeptide
09/12/2003WO2003074560A2 Critical hypoxia-inducible factor-1alpha residues, products and methods related thereto
09/12/2003WO2003074559A1 Falp proteins
09/12/2003WO2003074532A1 Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase
09/12/2003WO2003074531A1 Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
09/12/2003WO2003074517A1 Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
09/12/2003WO2003074513A2 Indole amide derivatives and their use as glycogen phosphorylase inhibitors
09/12/2003WO2003074504A2 Process and intermediates for preparing phenylthiomethyl-thiazoles or oxazoles
09/12/2003WO2003074495A1 Hppars activators
09/12/2003WO2003074489A1 Cyclic n-substituted alpha iminocarboxylic acids for selectively inhibiting collagenase
09/12/2003WO2003074485A2 Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
09/12/2003WO2003074484A1 Indolamid derivatives which possess glycogenphosphorylase inhibitory activity
09/12/2003WO2003074085A1 Tablets quickly disintegrating in oral cavity
09/12/2003WO2003074078A2 Cg3842 homologous proteins involved in the regulation of energy homeostasis
09/12/2003WO2003074071A1 Remedies for liver diseases, hyperlipemia and diabetes
09/12/2003WO2003074052A1 Thiazole and oxazole derivatives that modulate ppar activity
09/12/2003WO2003074051A1 Substituted thiazoles and oxazoles that modulate ppar activity
09/12/2003WO2003074050A1 Thiazole and oxazole derivatives which modulate ppar activity
09/12/2003WO2003074043A1 Body temperature elevating agents
09/12/2003WO2003074042A1 Uncoupling protein expression promoter
09/12/2003WO2003074034A1 Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release
09/12/2003WO2003074008A2 Aminoalkylphosphonates and related compounds as edg receptor agonists
09/12/2003WO2003073987A2 Compounds that modulate the activity of ptp-1b and tc-ptp
09/12/2003WO2003073986A2 Aminoalkylphosphonates and related compounds as edg receptor agonists
09/12/2003WO2003051828A3 (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
09/12/2003WO2003051389A3 Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
09/12/2003WO2003051333B1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
09/12/2003WO2003045942A3 Chemokine receptor antagonists and methods of use thereof
09/12/2003WO2003041684A3 Injectable depot compositions and uses thereof
09/12/2003WO2003039260A3 Probiotic compositions
09/12/2003WO2003037268A3 Hepta-, octa- and nonapeptides having antiangiogenic activity
09/12/2003WO2003034987A3 Androgen receptor modulators and methods of use thereof
09/12/2003WO2003032969A3 Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
09/12/2003WO2003028710A3 Compounds for reducing excessive intake of food
09/12/2003WO2002080979A3 Conjugate of hydroxyalkyl starch and an active agent
09/12/2003WO2002080966A3 Method for producing a vaccine containing autologous antibodies
09/12/2003WO2002058732B1 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
09/12/2003WO2002040486A3 METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS
09/12/2003WO2002032961A8 Novel polypeptides and nucleic acids encoding same
09/12/2003CA2478520A1 Thiazole and oxazole derivatives which modulate ppar activity
09/12/2003CA2478425A1 Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release
09/12/2003CA2478164A1 Substituted thiazoles and oxazoles that modulate ppar activity
09/12/2003CA2478101A1 Intraorally rapidly disintegrable tablets
09/12/2003CA2477969A1 Falp proteins
09/12/2003CA2477874A1 Expression cassette for persistence of expression of a gene of interest in muscle cells
09/12/2003CA2477854A1 Compositions and methods for treatment of body weight conditions with milk minerals and casein fractions
09/12/2003CA2477717A1 Indolamid derivatives which possess glycogen phosphorylase inhibitory activity
09/12/2003CA2477667A1 Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase
1 ... 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 ... 1298